Dr Reddy`s inks licensing pact with Takeda to sell gastrointestinal drug
Mankind Pharma Limited and Takeda Pharmaceutical Company Limited signed a Non-Exclusive Patent License Agreement for commercialising 'Vonoprazan' in the Indian market. The agreement allows Mankind Pharma to launch the novel drug for treating Gastroesophageal Reflux Disease (GERD) under its trademark.
HilleVax's stock took a nosedive after the vaccine biotech’s sole clinical-stage candidate failed a phase 2b trial in norovirus-related acute gastroenteritis (AGE).
Crosswalk Therapeutics has strolled over to Codexis to pick up Fabry and Pompe disease compounds that remain from an abandoned Takeda gene therapy collaboration. nnCodexis and Takeda had been working together to assess the biotech's recombinant AAV-based gene tech for the potential treatment of Fabry or Pompe disease. However, the future of the collaboration was thrown into doubt after the Japanese pharma announced in April 2023 that it was moving away from early-stage R&D work in adeno-associated virus-based gene therapies.
Just two months after telegraphing plans to lay off 641 staffers at two of its Massachusetts sites, Takeda is parting ways with another group of its workforce with more layoffs in the state. Elsewhere in Massachusetts, Merck KGaA’s biopharma subsidiary EMD Serono is set to do the same.
Silence Therapeutics has spoken up about its phase 1 polycythemia vera (PV) clinical trial, providing an early look at how its siRNA prospect may match up to rivals from Incyte and Takeda. nnPV patients undergo regular blood draws, a procedure known as a phlebotomy, to reduce the number of blood cells and decrease blood volume. At baseline, all subjects in Silence’s trial had undergone at least three phlebotomies in the past six months or five phlebotomies in the past year. In total, the participants underwent 59 blood draws in the six months before starting the study.
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Receives EU Approval for FRUZAQLA
Takeda Pharmaceutical`s Fruzaqla (fruquintinib) Receives Approval in Europe
BENGALURU, June 21 (Reuters) - Japan's Takeda Pharmaceutical (4502.T), opens new tab gave India's Sun Pharmaceutical (SUN.NS), opens new tab and Cipla (CIPL.NS), opens new tab the rights to commercialize gastrointestinal drug Vonoprazan in the country.